Search

everythinglearnresearchcommunity

for

Search:↓

The conclusion is that acne, alopecia, and hyperhidrosis are common skin issues with various treatments available, and accurate diagnosis is key for effective management.

Post-finasteride syndrome's existence is uncertain; more research needed.

A 65-year-old woman has a growing bald spot on her scalp.

The document explains various skin conditions and their treatments.

The document concludes that quick referral and appropriate treatments are crucial for managing common skin conditions and preventing permanent damage.

Finasteride can cause lasting sexual dysfunction, depression, and other side effects, needing more research for treatment.

Misinformation about alopecia can lead to poor treatment, so it's important for healthcare professionals to correct myths.

Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.

Using certain hair products may increase breast cancer risk in black women.

The CNC® prosthetic system improved body image in breast cancer patients with hair loss from chemotherapy but did not significantly change their psychological wellbeing.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Patients with HR+/HER2- advanced breast cancer commonly experience fatigue, hair loss, and pain, which significantly affect daily activities.

A woman's hair loss was initially mistaken for a common hair loss condition but was later found to be caused by breast cancer cells in her scalp.

Long-term estrogen therapy in postmenopausal women can improve certain health markers, hair loss is common regardless of hormone use, stopping estrogen doesn't increase breast cancer risk, smoking does, and a balanced BMI is linked to lower mortality.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

Spironolactone use is not linked to an increased risk of breast cancer, but caution is advised for high-risk patients.

Finasteride and dutasteride effectively treat hair loss in men and women, but may cause side effects like low libido and depression.

Estrogen-progestin contraception lowers ovarian, endometrial, and colon cancer risk but may raise breast and cervical cancer risk, helps with menstrual and acne issues, and new methods are as effective as pills. Metformin helps overweight women with PCOS and insulin resistance, and dopamine agonists treat prolactinomas.

Tamoxifen may cause female hair loss by increasing androgen receptor expression.

Adding stem cells to fat grafts for facial rejuvenation might improve outcomes, but more research is needed to confirm safety and effectiveness.

Most women undergoing chemotherapy experience hair loss, and many cope by using wigs or bonnets.

Cancer survivors often experience worse skin problems from treatment than expected, and working with dermatologists could help improve their condition.

Spironolactone is safe for breast cancer survivors with alopecia and does not increase cancer risk.

The document concludes that health care providers should offer culturally competent care and more research is needed to improve health outcomes for transgender individuals.

Cinnamon bark extract may help prevent weight loss and hair loss in breast cancer patients during chemotherapy and is safe to use.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.